EnGeneIC has recently completed a Phase I first-in-man clinical trial which proved the safety of its EDV technology.

EnGeneIC's mission is to change the perception of cancer from life threatening to curable. We are a privately held Australian company with proprietary technology based on bacterial minicells. These very small, 400 nanometre particles (EnGeneIC Delivery Vehicles or EDVs), are capable of carrying a payload of anticancer drugs and other therapeutic molecules such as siRNA/microRNA and plasmids and are targeted to tumour cells using antibodies.

Once injected into the blood stream, the EDVs passively accumulate around the tumour. When the antibodies attached to the EDVs bind onto the cancer cells, the EDVs are internalized and release their toxic payload. The EDV payload can be easily customised to provide combined therapies and because the chemotherapeutic agent is directed to where it is needed inside the cancer cell, a much smaller amount of drug and targeting antibody is used. This lowers costs while still retaining the therapeutic benefit to the patient. Production of EDVs is easily scalable and cost effective.